No Data
Oppenheimer Remains a Buy on Revolution Medicines (RVMD)
HC Wainwright & Co. Reiterates Buy on Revolution Medicines, Maintains $44 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Revolution Medicines (NASDAQ:RVMD) with a Buy and maintains $44 price target.
Buy Rating on Revolution Medicines With a $44 Target Amid Strong Financials and Upcoming Clinical Catalysts
Revolution Medicines Reports Q1 2024 Financial Results: Challenges and Strategic Advances in ...
Health Check: How Prudently Does Revolution Medicines (NASDAQ:RVMD) Use Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only n
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)